AnaptysBio completes $40M Series D; Piqur raises $19M to back cancer drug R&D;

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: Chatted a bit with Immunocore's CEO, also chairman of MedCity, about global/UK #biotech $$$. Story | Follow @JohnCFierce

> San Diego-based AnaptysBio wrapped an oversubscribed $40M Series D financing round. Participants include BVF Partners L.P., BioMed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and additional undisclosed investors. The cash will fuel work on AnaptysBio's anti-IL-33 and anti-IL-36 receptor antibody programs through Phase II. "The proceeds of this financing provide AnaptysBio with the financial strength to potentially demonstrate efficacy of our anti-IL-33 program in severe adult asthma and peanut allergy patients, while also advancing our anti-IL-36 receptor program to proof-of-concept in generalized pustular psoriasis," said CEO Hamza Suria. Release

> Switzerland's Piqur Therapeutics just raised $19 million for its cancer drug R&D specializing in PI3K and mTOR inhibition. The biotech has raised a total of $60 million and is pushing its lead therapy, PQR309, through mid-stage tests. Versant Ventures joined a syndicate behind the A2 round. Release

> Ewing, NJ-based Celator Pharmaceuticals has begun enrolling patients in a Phase II clinical study evaluating CPX-351 (cyatarabine:daunorubicin) Liposome Injection as a treatment for patients with newly diagnosed Acute Myeloid Leukemia. Release

Medical Device News

@FierceMedDev: ICYMI: Courtagen reels in $20M for genetic pediatric neurology disorder tests. Story  | Follow @FierceMedDev

@EmilyWFierce: Boom in specialty pharma business draws questions from consumers, lawmakers and patient advocates. NYT story | Follow @EmilyWFierce

> Alere keeps diagnostics ball rolling with new deals and quick strep test win. News

> Survey: Docs expect HeartWare's blood pump to get expanded indication from FDA despite worrying trial data. More

Pharma News

@FiercePharma: FDA may tap $GOOG to beef up drug-safety monitoring. Story | Follow @FiercePharma

@EricPFierce: Gallant Pharma owner notified in jail by #FDA he is disbarred for life from the pharma industry. Item | Follow @EricPFierce

@CarlyHFierce: Dont you dare think for a second that I passed up the chance to discuss the $GSK wolf grandma on @FierceBiotech Radio. Listen | Follow @CarlyHFierce

>Endo whistleblower nabs $33.6M from feds for 'extraordinary' work in FCA suit. More

> Sanofi says sweeping management revamp won't come with job cuts. Story

Vaccines News

> GSK, bioCSL to increase flu vaccine deliveries to U.S. More

> Reuters: WHO, EMA likely to approve GlaxoSmithKline's malaria vaccine despite challenges. News

> GSK and J&J/Bavarian Nordic take Ebola candidates to Senegal, Europe. More

> Expect vaccines market to swell to $40B by 2020: Tufts CSDD. Article

> EMA to again place HPV vaccines under its safety lens. Story

CRO News

> Icon and Covance bet on diagnostics with a pair of cancer deals. More

> Aptuit scales up its production prowess for Phase III trials. News

> Frontage buys into biometrics with BDM deal. Report

> Under new ownership, Synexus expands across Europe. Story

> WuXi bets $50M on a new venture fund and eyes $200M more. Article

Pharma Manufacturing News

> GSK ramps up flu vax production after problems last year. News

> American Health Packaging pulls thousands of Wockhardt-made products from the market. Story

> Mylan issues third reminder that 'lifesaving' syringes are being recalled. More

> J&J expects Fort Washington, PA, consumer plant to be back on line soon. Story

> Pfizer announces it will shutter India plant, echoing same news from Sandoz. Article

Pharma Asia News

> India's biopharma woes grow with FDA Emcure plant ban. More

> Japan's Takeda files ixazomib NDA for relapsed multiple myeloma. Report

> WuXi Healthcare Ventures plucks $50M from WuXi PharmaTech as anchor for second fund. Article

> Price controls fail to improve poor people's access to medicines in India, IMS report says. Story

> CFDA eyes new Shanghai evaluation center to speed drug approvals. More